Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amethyst study of quetiapine SR maintenance monotherapy in major depressive disorder
2005-003745-14Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Quetiapine SR maintenance with Placebo withdrawal control (2 arms). Primary endpoint: Time from randomisation to a depressed event. Started Nov 2005; status: completed.
02
Drugs
quetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2005-003745-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003745-14.